NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer's TKI Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage ...
Hosted on MSN
Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy
Pfizer (NYSE:PFE) on Tuesday announced that a Phase 3 trial designed to test its FDA-approved antitumor agent Tukysa as a first-line maintenance therapy in breast cancer reached its main goal with a ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained. Tukysa (tucatinib) may represent a new patient-friendly ...
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results